Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
FB

Fermenta Biotech Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Fermenta Biotech Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹156Cr
+58.1% YoY
+64.7% QoQ
Net profit
₹38Cr
+279.3% YoY
+240.7% QoQ
Margin
34.04%
+8.6 pp YoY
+14.3 pp QoQ

Based on Fermenta Biotech Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) - Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10) - Q3-FY25 revenue excluding real estate: I Q3-FY25 Consolidated Financials: - Operational EBITDA: INR 533 Mn (vs INR 252 Mn in Q3-FY24), showing strong YoY growth - Operational EBITDA Margin: 34.06% (vs 25.45% in Q3-FY24), an increase of

From Fermenta Biotech Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12)
  • Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10)
  • Q3-FY25 revenue excluding real estate: INR 118 crore (~INR 1,180 Mn), up 105% YoY (Page 8)
  • Human Nutrition volume growth: 102% over Q3-FY24 (Page 8)
  • Animal Nutrition volume growth: 4% over Q3-FY24 (Page 8)
  • 9M-FY25 consolidated operational revenue: INR 3,296 Mn, up 38.3% YoY (Page 13)

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

It mainly focuses on financial performance, operational highlights, geographical revenue mix, and business segments without mention of new capacity additions or capital expenditure plans. Key relevant points related to facilities or assets include: - Capital work-in-progress figures on balance sheet: INR 63 Mn (H1-FY25), INR 16 Mn (FY24), INR 419 Mn (FY23), indicating ongoing investments. - Transfer of leasehold land at Saykha, GIDC Gujarat completed with transfer value of INR 18.7 crore (post Q3-FY25).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q3 FY25 results — key figures

Fermenta Biotech Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue15699+58.1%95+64.7%
Operating profit (EBITDA)5325+112%19+183.7%
Operating margin34.04%25.39%+8.6 pp19.76%+14.3 pp
Profit before tax4516+182%12+283.6%
Net profit (PAT)3810+279.3%11+240.7%
EPS (₹)12.543.35+274.3%3.87+224%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharmaceuticals (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q3 FY25 results?

Q3-FY25 consolidated operational revenue: INR 1,565 Mn, up 58.1% YoY (Page 12) - Q3-FY25 standalone operational revenue: INR 1,463 Mn, up 63.6% YoY (Page 10) - Q3-FY25 revenue excluding real estate: I Q3-FY25 Consolidated Financials: - Operational EBITDA: INR 533 Mn (vs INR 252 Mn in Q3-FY24), showing strong YoY growth - Operational EBITDA Margin: 34.06% (vs 25.45% in Q3-FY24), an increase of

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.